Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKB | Q96GD4 | 10/20 | 0.85 |
| ▸ | MAPK1 | P28482 | 6/20 | 0.54 |
| ▸ | YES1 | P07947 | 2/20 | 0.54 |
| ▸ | HIPK1 | Q86Z02 | 1/20 | 0.54 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.53 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.53 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.53 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.53 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.48 |
| ▸ | ABL1 | P00519 | 1/20 | 0.46 |
| ▸ | PIM1 | P11309 | 1/20 | 0.46 |
| ▸ | GAK | O14976 | 2/20 | 0.44 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.43 |
| ▸ | RAF1 | P04049 | 1/20 | 0.43 |
| ▸ | BRAF | P15056 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1933460 | 0.92 | AURKB (1.00) | AURKBMAPK1YES1HIPK1PIK3CA | |
| SCHEMBL1932385 | 0.86 | AURKB (1.00) | AURKBMAPK1YES1NTRK1GAK | |
| SCHEMBL1933078 | 0.84 | AURKB (0.73) | AURKBMAPK1YES1NTRK1ABL1 | |
| SCHEMBL27886377 | 0.82 | AURKB (0.82) | AURKBMAPK1YES1HIPK1PIK3CA | |
| SCHEMBL1933012 | 0.80 | AURKB (0.66) | AURKBMAPK1ABL1 | |
| SCHEMBL1933613 | 0.79 | AURKB (0.65) | AURKBMAPK1PIK3CAMAPK8MAPK9 | |
| SCHEMBL4354044 | 0.79 | MAPK1 (0.69) | AURKBMAPK1YES1HIPK1PIK3CA | |
| SCHEMBL4341721 | 0.79 | MAPK1 (0.67) | AURKBMAPK1YES1HIPK1PIK3CA | |
| SCHEMBL1933604 | 0.78 | AURKB (1.00) | AURKBMAPK1YES1HIPK1NTRK1 | |
| SCHEMBL1932684 | 0.76 | AURKB (0.77) | AURKBMAPK1YES1PIK3CAMAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2504336-B1 | NOVEL NAPHTHYRIDINE DERIVATIVES AND THE USE THEREOF AS KINASE INHIBITORS | ÆTERNA ZENTARIS GMBH (DE) | 2016-03-30 | — | — | EP | claimed |
| US-20110150831-A1 | NOVEL NAPHTHYRIDINE DERIVATIVES AND THE USE THEREOF AS KINASE INHIBITORS | AETERNA ZENTARIS GMBH (DE) | 2011-06-23 | — | — | US | claimed |
| EP-2332939-A1 | Novel Naphthyridine derivatives and the use thereof as kinase inhibitors | Æterna Zentaris GmbH (DE) | 2011-06-15 | — | — | EP | claimed |
| EP-2504336-B1 | NOVEL NAPHTHYRIDINE DERIVATIVES AND THE USE THEREOF AS KINASE INHIBITORS | ÆTERNA ZENTARIS GMBH (DE) | 2016-03-30 | — | — | EP | disclosed |
| EP-2504336-B1 | NOVEL NAPHTHYRIDINE DERIVATIVES AND THE USE THEREOF AS KINASE INHIBITORS | ÆTERNA ZENTARIS GMBH (DE) | 2016-03-30 | — | — | EP | disclosed |
| US-8461178-B2 | Naphthyridine derivatives and the use thereof as kinase inhibitors | AETERNA ZENTARIS GMBH (DE) | 2013-06-11 | — | — | US | disclosed |
| US-8461178-B2 | Naphthyridine derivatives and the use thereof as kinase inhibitors | AETERNA ZENTARIS GMBH (DE) | 2013-06-11 | — | — | US | disclosed |
| US-8461178-B2 | Naphthyridine derivatives and the use thereof as kinase inhibitors | AETERNA ZENTARIS GMBH (DE) | 2013-06-11 | — | — | US | disclosed |
| EP-2504336-A1 | NOVEL NAPHTHYRIDINE DERIVATIVES AND THE USE THEREOF AS KINASE INHIBITORS | Æterna Zentaris GmbH (DE) | 2012-10-03 | — | — | EP | disclosed |
| US-20110150831-A1 | NOVEL NAPHTHYRIDINE DERIVATIVES AND THE USE THEREOF AS KINASE INHIBITORS | AETERNA ZENTARIS GMBH (DE) | 2011-06-23 | — | — | US | disclosed |
| US-20110150831-A1 | NOVEL NAPHTHYRIDINE DERIVATIVES AND THE USE THEREOF AS KINASE INHIBITORS | AETERNA ZENTARIS GMBH (DE) | 2011-06-23 | — | — | US | disclosed |
| US-20110150831-A1 | NOVEL NAPHTHYRIDINE DERIVATIVES AND THE USE THEREOF AS KINASE INHIBITORS | AETERNA ZENTARIS GMBH (DE) | 2011-06-23 | — | — | US | disclosed |
| EP-2332939-A1 | Novel Naphthyridine derivatives and the use thereof as kinase inhibitors | Æterna Zentaris GmbH (DE) | 2011-06-15 | — | — | EP | disclosed |
| EP-2332939-A1 | Novel Naphthyridine derivatives and the use thereof as kinase inhibitors | Æterna Zentaris GmbH (DE) | 2011-06-15 | — | — | EP | disclosed |
| WO-2011064250-A1 | NOVEL NAPHTHYRIDINE DERIVATIVES AND THE USE THEREOF AS KINASE INHIBITORS | ÆTERNA ZENTARIS GMBH (DE) | 2011-06-03 | — | — | WO | disclosed |
| WO-2011064250-A1 | NOVEL NAPHTHYRIDINE DERIVATIVES AND THE USE THEREOF AS KINASE INHIBITORS | ÆTERNA ZENTARIS GMBH (DE) | 2011-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110150831-A1 | NOVEL NAPHTHYRIDINE DERIVATIVES AND THE USE THEREOF AS KINASE INHIBITORS | MAP3K1, MAP3K20, MAP3K2 | AURKB 389/4885MAPK1 26/4885YES1 97/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.